Anzeige
Mehr »
Dienstag, 25.08.2026 - Börsentäglich über 12.000 News
Trommelwirbel! NurExone - jetzt wird es wirklich groß!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J5GZ | ISIN: SE0004840718 | Ticker-Symbol: 3XV
Stuttgart
24.08.26 | 21:55
25,140 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
XVIVO PERFUSION AB Chart 1 Jahr
5-Tage-Chart
XVIVO PERFUSION AB 5-Tage-Chart
RealtimeGeldBriefZeit
25,00025,76024.08.

Aktuelle News zur XVIVO PERFUSION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoXVIVO erhält CE-Zertifikate für bahnbrechende Technologie zur Herzkonservierung1.465Göteborg/Berlin (ots) - - Die CE-Zertifizierungen ermöglichen den breiteren Einsatz der innovativen XVIVO-Technologie und verbessert den Zugang zu Herztransplantationen in Europa. XVIVO gibt die CE-Zertifizierungen...
► Artikel lesen
11.08.Xvivo Perfusion AB: XVIVO receives CE certificates for its groundbreaking heart preservation technology, transforming access to life-saving transplants across Europe249CAUTION-Investigational device in the US. Limited by Federal (United States) law to investigational use. The safety and effectiveness of this device have not been established. The XVIVO heart technology...
► Artikel lesen
03.08.XVIVO Perfusion AB: XVIVO Granted Additional Patient Enrollment in the US PRESERVE CAP Study for XVIVO Heart Assist Transport345GOTHENBURG, SE / ACCESS Newswire / August 3, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - XVIVO announces that the US Food and Drug Administration (FDA) has granted the company approval...
► Artikel lesen
14.07.Xvivo Perfusion AB (publ) reports Q2 results3
14.07.Xvivo Perfusion AB Q2 Profit Rises3
XVIVO PERFUSION Aktie jetzt für 0€ handeln
14.07.XVIVO übertrifft im Q2 die Umsatzerwartungen dank starkem Thorax-Geschäft1
14.07.XVIVO Perfusion AB: Interim Report January - June 2026458GOTHENBURG, SE / ACCESS Newswire / July 14, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Second quarter 2026 (Apr-Jun)Net sales amounted to SEK 239.0 million (178.3), corresponding to a growth...
► Artikel lesen
09.07.OneLegacy Partners with XVIVO and Perfusion Solution to Launch the First Ex Vivo Lung Perfusion (EVLP) Center in the Western U.S.356OneLegacy, the nonprofit organ procurement organization serving Southern California, announced the launch of the first in-house Ex Vivo Lung Perfusion (EVLP) program at an organ procurement organization...
► Artikel lesen
26.06.XVIVO Perfusion AB: Conference call on Interim Report April-June 2026454GOTHENBURG, SE / ACCESS Newswire / June 26, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2026. The...
► Artikel lesen
18.05.XVIVO Perfusion AB: Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO's Heart Technology399GOTHENBURG, SE / ACCESS Newswire / May 18, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Hôpital La Pitié-Salpêtrière (Sorbonne University) in Paris, France, has, since the approval of...
► Artikel lesen
27.04.Bulletin from Annual General Meeting in XVIVO Perfusion AB323GOTHENBURG, SE / ACCESS Newswire / April 27, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV):The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion...
► Artikel lesen
24.04.Xvivo Perfusion AB (publ) GAAP EPS of SEK1.15, revenue of SEK241M1
24.04.XVIVO Perfusion AB: Interim Report January - March 2026216GOTHENBURG, SE / ACCESS Newswire / April 24, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2026 (Jan-Mar)Net sales amounted to SEK 241.0 million (218.6), corresponding to growth...
► Artikel lesen
24.04.Xvivo Perfusion AB: Interim Report January - March 2026232First quarter 2026 (Jan-Mar)• Net sales amounted to SEK 241.0 million (218.6), corresponding to growth of 10 percent in SEK.• Organic growth was 23 percent in local currencies. Excluding revenue from...
► Artikel lesen
22.04.XVIVO Perfusion AB: XVIVO Presents Encouraging Results From First Clinical Trial Using Hypothermic Oxygenated Perfusion In Direct Procurement DCD Heart Transplantation513GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, the results from the HOPE-at-Heart clinical trial (NCT06485596) were presented at the ISHLT...
► Artikel lesen
22.04.XVIVO Perfusion AB: Preliminary One-Year Follow-up Data From the US Preserve Trial for XVIVO's Heart Technology Presented at ISHLT in Toronto448GOTHENBURG, SE / ACCESS Newswire / April 22, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Today, preliminary one-year follow-up data from the US PRESERVE trial of XVIVO's investigational...
► Artikel lesen
22.04.Late-Breaking Data from PRESERVE Trial Evaluates XVIVO's HOPE Preservation Approach in Heart Transplantation469Preliminary results suggest potential to support extended preservation time and donor heart utilization XVIVO, a global medtech company in the organ transplant industry, today announced late-breaking...
► Artikel lesen
17.04.XVIVO Perfusion AB: Conference Call on Interim Report January-March 2026367GOTHENBURG, SE / ACCESS Newswire / April 17, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2026....
► Artikel lesen
16.04.XVIVO Perfusion AB: The 12-Month Follow-up Results from XVIVO's European Multicenter Heart Trial is Now Published in the European Heart Journal354GOTHENBURG, SE / ACCESS Newswire / April 16, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - At last year's ISHLT congress, in April 2025, the one-year results from the European multicenter...
► Artikel lesen
02.04.Xvivo Perfusion AB (publ) GAAP EPS of SEK 0.80, revenue of SEK 812.2M4
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1